Molecular Properties
| Parameter | Value |
|---|---|
| Chemical Name | Metastin (45-54) / Kisspeptin-10 |
| Amino Acid Sequence | Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH₂ |
| Molecular Formula | C₆₃H₈₃N₁₇O₁₄ |
| Molecular Weight | 1302.45 g/mol |
| CAS Number | 374675-21-5 |
| Sequence Length | 10 amino acids (C-terminal decapeptide) |
| Receptor Target | KISS1R (GPR54) |
Physical Properties
| Property | Specification |
|---|---|
| Appearance | White to off-white lyophilized powder |
| Solubility | Soluble in sterile water, PBS (pH 7.0-7.4), or 0.9% saline at ≥1 mg/mL |
| pH (1% solution) | 5.5 - 7.0 |
| Hygroscopicity | Moderate; store in desiccated environment |
| Solution Stability | Stable at 4°C for 48-72 hours after reconstitution |
Analytical Specifications
| Test | Specification |
|---|---|
| HPLC Purity | ≥98.0% |
| Mass Spectrometry | Confirmed [M+H]⁺ = 1302.45 ± 0.5 Da |
| Peptide Content | ≥95% (by amino acid analysis) |
| Endotoxin Level | <1.0 EU/mg |
| Acetate Content | ≤5% |
| TFA Content | ≤0.1% |
| Water Content | ≤8% (Karl Fischer) |
Storage Parameters
| Condition | Specification |
|---|---|
| Lyophilized Storage | -20°C to -80°C, desiccated |
| Lyophilized Shelf Life | 24-36 months when stored properly |
| Reconstituted Storage | 2-8°C for up to 14 days; -20°C for up to 3 months |
| Analytical Stock Preparation | Dissolve in sterile water or PBS (pH 7.0-7.4) with gentle vortexing for 30-60 seconds |
| Freeze-Thaw Cycles | Avoid multiple cycles; single-use aliquoting recommended |
| Light Sensitivity | Protect from direct light; store in amber vials |
In Vitro & Preclinical Model Concentrations
| Experimental Model | Published Concentration / Regimen | Exposure Schedule | Administration Context |
|---|---|---|---|
| In Vitro Cell Studies | 10-1000 nM | Single or repeated exposure | Culture media |
| Small Animal Models (Rodent) | 0.1-10 nmol/animal (50-500 μg/kg) | Once daily to BID | IP, SC, IV in rodent models |
| GnRH Stimulation Studies (Animal) | 1-10 nmol/kg | Acute or pulsatile | IV bolus in animal models |
| Reproductive Axis Research (Rodent) | 0.5-5 nmol/kg | Daily for 7-14 days | SC in rodent models |
Note: Concentrations and animal regimens summarized above are for research reference only. Kisspeptin-10 is intended strictly for in vitro and animal research purposes and is not approved for human therapeutic use.
Key Research Studies
| Year | Study Focus | Key Findings |
|---|---|---|
| 2005 | GPR54 receptor activation and GnRH secretion | Demonstrated that kisspeptin-10 is the minimal active fragment capable of stimulating GnRH neurons and triggering LH release with EC₅₀ ~1 nM at GPR54 receptor |
| 2011 | Hypothalamic-pituitary-gonadal axis regulation | Investigational IV administration of kisspeptin-10 (0.01-1 nmol/kg) dose-dependently increased LH and FSH in clinical research subjects; effects blocked by GnRH antagonists |
| 2015 | Metabolic and reproductive integration | Kisspeptin-10 infusion modulated both reproductive hormone secretion and metabolic parameters; demonstrated cross-talk between energy balance and fertility pathways |
| 2018 | Structure-activity relationship analysis | C-terminal Arg-Phe-NH₂ motif identified as critical for receptor binding; N-terminal modifications reduced potency by 10-100 fold compared to native kisspeptin-10 |
Mechanism of Action
| Biological Pathway | Description |
|---|---|
| Receptor Binding | High-affinity agonist at KISS1R (GPR54), a Gq-coupled GPCR expressed on GnRH neurons |
| Signal Transduction | Activates phospholipase C → IP₃/DAG pathway → Ca²⁺ mobilization → neuronal depolarization |
| GnRH Release | Direct stimulation of GnRH neurons in arcuate nucleus and AVPV; triggers GnRH pulsatile secretion |
| Downstream Effects | LH and FSH release from pituitary gonadotrophs; subsequent gonadal steroidogenesis |
| Half-Life | ~30-40 minutes (IV); rapid degradation by peptidases |
Regulatory & Compounding Status (April 2026)
On FDA’s page on bulk drug substances used in compounding, current as of April 22, 2026, kisspeptin-10 is listed in Category 2 under 503A (bulk drug substances that raise significant safety risks in compounding). Kisspeptin-10 is not approved by the U.S. FDA for human or veterinary therapeutic use. This monograph is intended strictly for laboratory research.
External References
- National Center for Biotechnology Information. PubChem Compound Summary for Kisspeptin-10. https://pubchem.ncbi.nlm.nih.gov/compound/Kisspeptin-10
- Seminara SB, et al. The GPR54 gene as a regulator of puberty. N Engl J Med. 2003;349(17):1614-27. https://www.nejm.org/doi/full/10.1056/NEJMoa035322
- Jayasena CN, et al. Kisspeptin-54 triggers egg maturation in women undergoing in vitro fertilization. J Clin Invest. 2014;124(8):3667-77. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4109546/
